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Reply to Hofmann et al.
To the Editor:
In the June issue of the Journal, Hofmann et al. (1997)
commented on our study of Leber hereditary optic neu-
ropathy (LHON; MIM 535000 [http://www3.ncbi
.nlm.nih.gov:80/htbin-post/Omim/dispmim?535000])
multigeneration pedigrees (Mackey et al. 1996). Hof-
mann et al. made two main points in their letter, the first
of which was that a mutation at nucleotide 15257 of
the mitochondrial cytochrome b gene has a pathogenic
role in LHON. This is a long-standing and unresolved
controversy that epitomizes the pitfalls that beset the
identification of pathogenic mtDNA mutations. Their
second point, which is not an issue that we addressed,
was that “so-called” secondary LHON mutations, in
their terminology, play an etiologic role in other neu-
rological disorders.
There is broad agreement that mtDNA mutations at
nucleotides 3460, 11778, and 14484 are pathogenic
LHON mutations, but there is disagreement over the
pathogenic role of the 15257 mutation (Howell 1994,
1997a; Oostra et al. 1994). In our previous reports, in-
cluding that by Mackey et al. (1996), the term “primary”
was applied to the 3460, 11778, and 14484 LHON
mutations. LHON is maternally inherited, but the pen-
etrance is incomplete. The pathogenic mtDNA mutation
is thus the predominant risk factor, but additional eti-
ologic factors are required for manifestation of the optic
neuropathy (Howell et al. 1997a, 1997b). In that sense,
the 3460, 11778, and 14484 mtDNA mutations have a
primary pathogenic role in LHON. Several additional
mtDNA mutations have been identified that may have
an etiologic or pathogenic role in LHON, including some
that may augment or modify the phenotypic effects of
the three known pathogenic mutations (see below). As
a result of this uncertainty, the nomenclature has become
commensurately more complicated. For example, Brown
and Wallace (1994) list 16 mutations that have primary,
secondary, or intermediate roles in LHON, although
even this list is now incomplete (e.g., see Howell et al.
1998, and references therein).
The purpose of our previous study (Mackey et al.
1996) was to identify the pathogenic mtDNA mutations
in LHON pedigrees. A total of 159 families (comprising
∼12,000 maternal relatives) from Australia and northern
Europe were analyzed, because these are countries where
extensive genealogies are more easily obtained. We lim-
ited our study to large multigeneration LHON families,
to avoid the ambiguities that arise with singleton cases
of bilateral optic neuropathy in which maternal inher-
itance is lacking. The majority of sporadic cases of a
LHON-like optic atrophy are not associated with the
3460, 11778, or 14484 LHON mutations (Chan et al.
1996). None of these 159 LHON families carried the
15257 mutation in the absence of one of the three pre-
viously established LHON mutations, although it was
associated with one of the three mutations in six LHON
families. This association has also been found in other
LHON families (Howell et al. 1993; Oostra et al. 1994),
as well as among those analyzed by Hofmann et al.
(1997). The penetrance of pathogenic mutations is not
increased in the LHON families whose mtDNAs also
harbor the 15257 mutation (e.g., see Howell et al. 1993;
Torroni et al. 1997). These negative results argue against
a pathogenic role for the 15257 mutation, because
LHON is a disorder whose penetrance is particularly
dependent on the action of secondary etiologic factors
(Howell 1997a, 1997b).
In contrast to our results, Obermaier-Kusser et al.
(1994) reported a LHON family, with multiple affected
family members that span multiple generations, that car-
ries the 15257 mutation but not one of the three pre-
viously identified pathogenic LHON mutations. Hof-
mann et al. (1997) report a total of 55 optic neuropathy
index cases, 3 of which are 15257 plus 11778 and 6 of
which are 15257 plus 14484, but 5 of which are “15257
only.” It is not clear whether these 15257-only cases are
distant relatives of the LHON family described else-
where (Obermaier-Kusser et al. 1994) or have affected
maternal relatives. It is precisely because of the experi-
mental and analytical difficulties inherent to singleton
cases that we undertook our study of multigeneration
families. More important, sequencing analysis has not
been performed, either for the 15257-only LHON family
or for the new 15257 cases, and the presence of a rare,
unidentified pathogenic mutation cannot be ruled out.
The 15257 mutation has been detected at a low fre-
quency (Brown et al. 1992; Kalman et al. 1995; and
especially see Torroni et al. 1997) in normal control
subjects, a result that argues against a pathogenic role.
However, population surveys of normal controls should
capture individuals who harbor a pathogenic LHON
mutation but who, because of the incomplete pene-
trance, are not clinically affected. The 3460, 11778, and
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14484 LHON mutations, which tend to produce a rel-
atively high-penetrance form of LHON (Mackey 1994;
Chan et al. 1996), have not yet been detected in such
surveys. If the 15257 mutation produces an unusually
low-penetrance form of LHON, this would explain both
the absence of 15257-only multigeneration LHON fam-
ilies in our survey and the presence of the 15257 mu-
tation in normal control populations. That explanation,
however, does not fit the observation that the 15257
LHON family of Obermaier-Kusser et al. (1994) has a
high penetrance.
Hofmann et al. (1997) also discuss haplogroup clus-
tering and the 15257 mutation. Haplogroup clustering
was first reported by Johns and Berman (1991), who
showed that the frequency of what they termed second-
ary LHON mutations at nucleotides 4216 and 13708
were associated more often with 11778 LHON patients
than with normal controls. It is now recognized that the
4216 and 13708 sequence changes define one of the
major European haplogroups (designated “A” by Hof-
mann et al. [1996], “2A” by Richards et al. [1996], and
“J” by Torroni et al. [1996]). Both the 11778 and 14484
mutations cluster, or are associated preferentially, with
this haplogroup, and ∼75% of 14484 LHON patients
or pedigrees carry mitochondrial genomes that belong
to this haplogroup (Johns 1994; Brown et al. 1997; Tor-
roni et al. 1997). There is no satisfactory explanation
for this clustering, although it has been proposed that
one or more of the mtDNA sequence changes in this
haplogroup markedly increases the penetrance of the
11778 and 14484 LHON mutations, particularly in the
case of the latter (Brown et al. 1997; Torroni et al. 1997).
The 15257 mutation, with rare exception, is also as-
sociated with this haplogroup (Howell et al. 1995;
Brown et al. 1997; Torroni et al. 1997).
In addition to haplogroup J, there is a second hap-
logroup, which carries the mutation at nucleotide 4216
and a mutation at nucleotide 4917 (designated “B” by
Hofmann et al. [1997], “2B” by Richards et al. [1996],
and “T” by Torroni et al. [1996]). We (Howell et al.
1995), Hofmann et al. (1997), and Richards et al. (1996)
agree that European haplogroups J and T are members
of the same phylogenetic cluster (but, for the alternative
view that the two haplogroups are less closely related,
see Torroni et al. [1996, 1997]). It was initially con-
cluded that there was also clustering of LHON muta-
tions with the 42164917 combination of mutations
(Johns and Berman 1991), but more-recent results do
not support this conclusion (Torroni et al. 1997). Hof-
mann et al. (1997) report two LHON patients in whom
the 15257 LHON mutation is associated with the mu-
tation at nucleotide 4917. Furthermore, they state that
one of these patients did not carry a LHON mutation
at nucleotide 3460, 11778, or 14484. It is difficult to
assess the ramifications of those results, but Torroni et
al. (1997) have reported the 491715257 combination
in a normal control. Furthermore, Torroni et al. (1997)
have shown that the mitochondrial genomes from their
LHON pedigrees cluster with the haplogroup J sub-
branch that does not carry the 15257 mutation (see their
fig. 2), results that imply that the 15257 mutation does
not increase LHON penetrance (see above).
The second major point raised by Hofmann et al.
(1997, p. 1540) is that secondary LHON mutations are
frequently associated with non-LHON neurological dis-
orders. As evidence for this proposition, they cite recent
studies that found an increased frequency of the 15257
and 13708 mutations, both in a cohort of patients with
multiple sclerosis (MS) and visual impairment (Mayr-
Wohlfart et al. 1996) and in a group of patients with
varied neurodegenerative disorders (Ro¨del et al. 1996).
However, even if the results of Kalman et al. (1995) and
Mayr-Wohlfart et al. (1996) are pooled, there is no sta-
tistically significant association between the 15257 mu-
tation and MS (data not shown). Second, there is no
significant association between the 13708 mutation and
MS in the pooled data from these two studies, nor when
they are pooled with the much larger study by Kellar-
Wood et al. (1994). It is also possible to use the pooled
data of Kalman et al. (1995) and Mayr-Wohlfart et al.
(1996) to show that there is no significant association
between MS and haplotype J (data not shown). Ro¨del
et al. (1996) have reported that 7 of 200 neurology pa-
tients from a southern German population harbor
mtDNAs with the 1370815257 array of secondary
LHON mutations, although the frequency of this com-
bination of sequence changes among normals from the
same geographic region is not specified. Richards et al.
(1996) have shown that haplogroup J (which they term
“2A”) has a heterogeneous geographic distribution
throughout Europe and the Middle East, and the results
of Ro¨del et al. (1996) thus require wider surveys of hap-
logroup J population samples.
Hofmann et al. (1997) have reported that the mtDNA
from five of their eight patients with DIDMOAD (dia-
betes insipidus, diabetes mellitus, optic atrophy, and
deafness) belong to the 42164917 haplogroup (hap-
logroup T of Torroni et al. [1996]), a frequency (63%)
much higher than the frequency (9%) of this haplogroup
among the controls in their study. In addition, there ap-
pears to be an increased frequency of MS patients with
mtDNAs who belong to this haplogroup (Kalman et al.
1995; Mayr-Wohlfart et al. 1996). In these two studies,
the pooled frequencies were 16/153 in MS patients and
7/174 in the controls ( , as determined by a x2P ! .05
test). Hofmann et al. thus conclude that the 4216, 4917,
and 13708 sequences are not secondary LHON muta-
tions but that, instead, they are mtDNA mutations that
have an etiologic role (possibly secondary) in a variety
of neurological disorders. We believe that such a con-
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clusion is premature and that more-extensive screening
of both patients and controls from geographically di-
verse European subpopulations is required. For example,
mtDNA haplotype analysis of another set of 28 Cau-
casian DIDMOAD patients has not revealed haplotype
clustering (J. Poulton and T. Barratt, unpublished data).
Especially within small geographic areas, there may be,
between nuclear genotypes and mitochondrial haploty-
pes, preferential associations that may be statistically
significant but that do not signal an etiologic role for
the mitochondrial genome in the disease process (for an
analysis of the relative nuclear and mitochondrial genetic
contributions from founders in isolated populations, see
Heyer [1995]).
In summary, it is our view that the available data do
not yet indicate that the 4216, 4917, 13708, and 15257
mutations (and any sequence changes associated with
haplogroups J and T) are pathogenic, either in LHON
or in other neurological abnormalities. We agree with
Hofmann et al. (1997) that further investigation is
warranted.
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Characterization of 10p Deletions Suggests Two
Nonoverlapping Regions Contribute to the DiGeorge
Syndrome Phenotype
To the Editor:
DiGeorge syndrome (DGS; MIM 188400 [http://
www3.ncbi.nlm.nih.gov:80/htbin-post/Omim/dispmim
?188400]) is a developmental-field defect characterized
by abnormalities of structures derived from the pharyn-
geal arches and pouches (for a review, see Driscoll and
Emanuel 1996). The vast majority of individuals with
DGS have been found to have deletions of chromosomal
region 22q11.2. However, a small number of patients
have been shown to have deletions of chromosome 10p,
with normal chromosome 22s (for a review, see Green-
berg et al. 1988). We report here the location and extent
of the deletion on chromosome 10, determined by means
of a combination of heterozygosity tests and FISH anal-
ysis, in five DGS patients. Our results do not support
the existence of a single, commonly deleted region on
10p in these five patients. Rather, they suggest that de-
letion of more than one region on chromosome 10p can
be associated with the DGS phenotype.
We examined the extent of the chromosome-10p de-
letions in five patients. Phenotypic characterizations of
three (GM6936, CH92-304, and CH95-199) of the five
patients were reported elsewhere, by Greenberg et al.
(1986), by Monaco et al. (1991) and Pignata et al.
(1996), and by Lipson et al. (1996), respectively. Mo-
lecular characterizations of the deletions present in
GM6936 and CH95-199 were also reported by Daw et
al. (1996). Patient CH95-199 is designated as “P3” in
Daw et al. (1996). The remaining two patients were
referred to us after their deletions were detected by
means of high-resolution cytogenetic analysis. All of the
patients exhibit at least one of the classic features of
DGS (cardiac defect, hypocalcemia, and/or immune de-
fect). Clinical findings are summarized in table 1.
We first performed heterozygosity mapping by use of
markers between loci D10S249 and D10S213. These
sequence-tagged sites (STSs) correspond roughly to the
cytogenetic location 10p15-10p12 (Chumakov et al.
1995). Three of the five patients had a single allele for
the three most distal markers, D10S249, D10S591, and
D10S189; this finding is consistent with a terminal de-
letion of 10p (table 2). The remaining two patients were
heterozygous, at loci D10S249, D10S591, and
D10S189, but had single alleles for a series of more
centromeric markers (table 2); this finding is consistent
with the presence of an interstitial deletion. As shown
in table 2, there is no marker for which all patients have
a single allele, which suggests that there is no common
region-of-deletion overlap among these five patients.
To confirm the heterozygosity-mapping results, we
performed FISH analysis on these five patients, using
YACs from the region. All YACs were from the CEPH/
Genethon megaYAC library, except 194G1, which was
isolated from the smaller-insert CEPH library. FISH
analysis confirmed and extended the results obtained
from the heterozygosity tests: there is no common region
of overlap among all five patients (fig. 1). Four of the
five patients have a common region of deletion that in-
cludes the shortest region-of-deletion overlap (SRO) de-
scribed in Daw et al. (1996). Two of these four patients,
GM6936 and CH95-199 (“P3”), were included in Daw
et al. (1996), and the other two do not narrow the SRO
further. Patient CH92-092, although without a deletion
for this SRO, does share an extensive region of deletion
with the other two patients with terminal deletions. Fur-
ther, it is possible that there is a small region-of-deletion
overlap between CH92-092 and CH92-304. The end-
points of the deletions in these two patients could not
be defined precisely because the YAC contig is not con-
tinuous from D10S1431 to D10S226. On the basis of
the results presented here, it is not possible to attribute
